The aim was to compare efficacy of treatments for diabetic macular oedema (DMO) from changes in visual acuity (VA) and central macular thickness (CMT). Peer-reviewed articles from 2004 to 2014 reporting intravitreal injections of bevacizumab (IVB), ranibizumab (IVR) or triamcinolone acetonide (IVTA) or laser photocoagulation therapy (LPT) provided data on pre-treatment (baseline) and final outcome measures. Net changes and relative changes (percentage) were assessed by linear regression analyses.
- anti-VEGF treatments, corticosteroid treatments, diabetic macular oedema, laser photocoagulation
Bong, A., Doughty, M., Button, N., & Mansfield, D. (2016). On the relationship between visual acuity and central retinal (macular) thickness after interventions for macular oedema in diabetics: a review. Clinical and Experimental Optometry, 99(6), 491-497. https://doi.org/10.1111/cxo.12393